Silexion Therapeutics Ltd.
SLXNW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $25 | $0 | $0 | $0 |
| Gross Profit | -$25 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,815 | $3,708 | $0 | $0 |
| G&A Expenses | $0 | $928 | $0 | $0 |
| SG&A Expenses | $6,731 | $928 | $1,232 | $944 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $45 | $0 | $0 |
| Operating Expenses | $12,546 | $4,681 | $1,232 | $944 |
| Operating Income | -$12,571 | -$4,681 | -$1,232 | -$944 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,938 | -$395 | $1,816 | $189 |
| Pre-Tax Income | -$16,509 | -$5,076 | $584 | -$755 |
| Tax Expense | $10 | $32 | $0 | $0 |
| Net Income | -$16,443 | -$4,942 | $584 | -$755 |
| % Margin | – | – | – | – |
| EPS | 25.49 | 0.39 | 0.35 | -0.46 |
| % Growth | 6,435.9% | 11.4% | 176.1% | – |
| EPS Diluted | 25.49 | 0.39 | 0.35 | -0.46 |
| Weighted Avg Shares Out | 624 | 681 | 1,673 | 1,651 |
| Weighted Avg Shares Out Dil | 624 | 681 | 1,673 | 1,651 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $153 | $1,686 | $6 |
| Interest Expense | $52 | $9 | $0 | $0 |
| Depreciation & Amortization | $25 | $45 | $0 | $0 |
| EBITDA | -$16,432 | -$4,636 | $584 | -$755 |
| % Margin | – | – | – | – |